Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion recommending approval of Keytruda, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2-positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Pfizer price target lowered to $42 from $43 at Morgan Stanley
- Merck price target lowered to $116 from $118 at Truist
- Merck announces Phase 3 KEYNOTE-A18 trial met one primary endpoint
- Johnson & Johnson Stock (NYSE:JNJ): Medicare Negotiations and Q2 Earnings in Focus
- Merck price target raised to $113 from $102 at BMO Capital